EC approves Xtandi

Astellas Pharma Inc. (Tokyo:4503) and partner Medivation Inc. (NASDAQ:MDVN) said the European Commission approved an MAA for Xtandi enzalutamide to treat metastatic castration-resistant prostate cancer (CRPC) in men whose disease has progressed on or after docetaxel therapy. The approval triggered a $15 million milestone payment to Medivation from Astellas. The companies partnered to develop and commercialize Xtandi in 2009. FDA approved the oral androgen receptor antagonist for the indication last August. ...